Sen. Dan Kotowski
Filed: 4/11/2011
 
 

 

 

 
09700SB0670sam001LRB097 04433 CEL 54208 a



1
AMENDMENT TO SENATE BILL 670




2    AMENDMENT NO. ______. Amend Senate Bill 670 by replacing 
3everything after the enacting clause with the following:

 
4    "Section 5. The Pharmacy Practice Act is amended  by 
5changing Section 26 as follows:
 
6    (225 ILCS 85/26)
7    (Section scheduled to be repealed on January 1, 2018)
8    Sec. 26. Anti-epileptic drug product selection prohibited.
9    (a) The General Assembly finds that this Section is 
10necessary for the immediate preservation of the public peace, 
11health, and safety.
12    (b) In this Section:
13    "Anti-epileptic drug" means (i) any drug prescribed for the 
14treatment of epilepsy or (ii) a drug used to treat or prevent 
15seizures.
16    "Epilepsy" means a neurological condition characterized by 
 
 
09700SB0670sam001- 2 -LRB097 04433 CEL 54208 a

1recurrent seizures.
2    "Seizure" means a brief disturbance in the electrical 
3activity of the brain.
4    (c) When the prescribing physician has indicated on the 
5original prescription "may not substitute", a pharmacist may 
6not interchange an anti-epileptic drug or formulation of an 
7anti-epileptic drug for the treatment of epilepsy without 
8notification and the documented consent of the prescribing 
9physician and the patient or the patient's parent, legal 
10guardian, or spouse.
This Section does not apply to medication 
11orders issued for anti-epileptic drugs for any in-patient care 
12in a licensed hospital.

13    (d) If a pharmacist substitutes any generic prescription in 
14place of a brand-name anti-epileptic drug, then the pharmacist 
15shall provide written notice to the patient no later than the 
16time the prescription is dispensed. 
17(Source: P.A. 94-936, eff. 6-26-06; 95-689, eff. 10-29-07.)".